Barry L Carter1, Christopher S Coffey2, Gail Ardery2, Liz Uribe2, Dixie Ecklund2, Paul James2, Brent Egan2, Mark Vander Weg2, Elizabeth Chrischilles2, Thomas Vaughn2. 1. From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City (B.L.C., G.A.); Departments of Family Medicine (B.L.C., P.J.) and Internal Medicine (M.V.W.), Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City; Departments of Biostatistics (C.S.C., L.U., D.E.), Epidemiology (E.C.), and Health Management and Policy (T.V.), College of Public Health, University of Iowa, Iowa City; Department of Psychology (M.V.W.) and Organizations, Systems, and Community Health Area, College of Nursing (T.V.), University of Iowa, Iowa City; The Center for Comprehensive Access & Delivery Research and Evaluation, Iowa City Veterans Administration, IA (B.L.C., M.V.W.); and Department of Internal Medicine, University of South Carolina School of Medicine, Greenville (B.E.). barry-carter@uiowa.edu. 2. From the Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City (B.L.C., G.A.); Departments of Family Medicine (B.L.C., P.J.) and Internal Medicine (M.V.W.), Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City; Departments of Biostatistics (C.S.C., L.U., D.E.), Epidemiology (E.C.), and Health Management and Policy (T.V.), College of Public Health, University of Iowa, Iowa City; Department of Psychology (M.V.W.) and Organizations, Systems, and Community Health Area, College of Nursing (T.V.), University of Iowa, Iowa City; The Center for Comprehensive Access & Delivery Research and Evaluation, Iowa City Veterans Administration, IA (B.L.C., M.V.W.); and Department of Internal Medicine, University of South Carolina School of Medicine, Greenville (B.E.).
Abstract
BACKGROUND: The purpose of this study was to evaluate if a physician/pharmacist collaborative model would be implemented as determined by improved blood pressure (BP) control in primary care medical offices with diverse geographic and patient characteristics and whether long-term BP control could be sustained. METHODS AND RESULTS: Prospective, cluster-randomized trial of 32 primary care offices stratified and randomized to control, 9-month intervention (brief), and 24-month intervention (sustained). We enrolled 625 subjects with uncontrolled hypertension; 54% from racial/ethnic minority groups and 50% with diabetes mellitus or chronic kidney disease. The primary outcome of BP control at 9 months was 43% in intervention offices (n=401) compared with 34% in the control group (n=224; adjusted odds ratio, 1.57 [95% confidence interval, 0.99-2.50]; P=0.059). The adjusted difference in mean systolic/diastolic BP between the intervention and control groups for all subjects at 9 months was -6.1/-2.9 mm Hg (P=0.002 and P=0.005, respectively), and it was -6.4/-2.9 mm Hg (P=0.009 and P=0.044, respectively) in subjects from racial or ethnic minorities. BP control and mean BP were significantly improved in subjects from racial minorities in intervention offices at 18 and 24 months (P=0.048 to P<0.001) compared with the control group. CONCLUSIONS: Although the results of the primary outcome (BP control) were negative, the key secondary end point (mean BP) was significantly improved in the intervention group. Thus, the findings for secondary end points suggest that team-based care using clinical pharmacists was implemented in diverse primary care offices and BP was reduced in subjects from racial minority groups. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00935077.
RCT Entities:
BACKGROUND: The purpose of this study was to evaluate if a physician/pharmacist collaborative model would be implemented as determined by improved blood pressure (BP) control in primary care medical offices with diverse geographic and patient characteristics and whether long-term BP control could be sustained. METHODS AND RESULTS: Prospective, cluster-randomized trial of 32 primary care offices stratified and randomized to control, 9-month intervention (brief), and 24-month intervention (sustained). We enrolled 625 subjects with uncontrolled hypertension; 54% from racial/ethnic minority groups and 50% with diabetes mellitus or chronic kidney disease. The primary outcome of BP control at 9 months was 43% in intervention offices (n=401) compared with 34% in the control group (n=224; adjusted odds ratio, 1.57 [95% confidence interval, 0.99-2.50]; P=0.059). The adjusted difference in mean systolic/diastolic BP between the intervention and control groups for all subjects at 9 months was -6.1/-2.9 mm Hg (P=0.002 and P=0.005, respectively), and it was -6.4/-2.9 mm Hg (P=0.009 and P=0.044, respectively) in subjects from racial or ethnic minorities. BP control and mean BP were significantly improved in subjects from racial minorities in intervention offices at 18 and 24 months (P=0.048 to P<0.001) compared with the control group. CONCLUSIONS: Although the results of the primary outcome (BP control) were negative, the key secondary end point (mean BP) was significantly improved in the intervention group. Thus, the findings for secondary end points suggest that team-based care using clinical pharmacists was implemented in diverse primary care offices and BP was reduced in subjects from racial minority groups. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00935077.
Authors: Barry L Carter; William Clarke; Gail Ardery; Cynthia A Weber; Paul A James; Mark Vander Weg; Elizabeth A Chrischilles; Thomas Vaughn; Brent M Egan Journal: Circ Cardiovasc Qual Outcomes Date: 2010-07
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: Barry L Carter; William R Doucette; Carrie L Franciscus; Gail Ardery; Karen M Kluesner; Elizabeth A Chrischilles Journal: Pharmacotherapy Date: 2010-03 Impact factor: 4.705
Authors: Shannon J Von Muenster; Barry L Carter; Cynthia A Weber; Michael E Ernst; Jessica L Milchak; Jennifer J G Steffensmeier; Yinghui Xu Journal: Pharm World Sci Date: 2007-08-21
Authors: Krista K Proia; Anilkrishna B Thota; Gibril J Njie; Ramona K C Finnie; David P Hopkins; Qaiser Mukhtar; Nicolaas P Pronk; Donald Zeigler; Thomas E Kottke; Kimberly J Rask; Daniel T Lackland; Joy F Brooks; Lynne T Braun; Tonya Cooksey Journal: Am J Prev Med Date: 2014-06-02 Impact factor: 5.043
Authors: Barry L Carter; Gail Ardery; Jeffrey D Dawson; Paul A James; George R Bergus; William R Doucette; Elizabeth A Chrischilles; Carrie L Franciscus; Yinghui Xu Journal: Arch Intern Med Date: 2009-11-23
Authors: Lori M Dickerson; Connie Kraus; Grace M Kuo; Cynthia A Weber; Oralia V Bazaldua; John M Tovar; Anne L Hume; Timothy J Ives; John G Gums; Barry L Carter Journal: Am J Health Syst Pharm Date: 2007-10-01 Impact factor: 2.637
Authors: Barry L Carter; George R Bergus; Jeffrey D Dawson; Karen B Farris; William R Doucette; Elizabeth A Chrischilles; Arthur J Hartz Journal: J Clin Hypertens (Greenwich) Date: 2008-04 Impact factor: 3.738
Authors: Barry L Carter; Barcey Levy; Brian Gryzlak; Yinghui Xu; Elizabeth Chrischilles; Jeffrey Dawson; Mark Vander Weg; Alan Christensen; Paul James; Linnea Polgreen Journal: Circ Cardiovasc Qual Outcomes Date: 2018-06
Authors: Dalia M Dawoud; Alexander Haines; David Wonderling; Joanna Ashe; Jennifer Hill; Mihir Varia; Philip Dyer; Julian Bion Journal: Pharmacoeconomics Date: 2019-10 Impact factor: 4.981
Authors: Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress Journal: Curr Hypertens Rep Date: 2019-11-07 Impact factor: 5.369
Authors: Katherine J Overwyk; Steven P Dehmer; Kakoli Roy; Michael V Maciosek; Yuling Hong; Madeleine M Baker-Goering; Fleetwood Loustalot; Christa-Marie Singleton; Matthew D Ritchey Journal: Med Care Date: 2019-11 Impact factor: 2.983
Authors: Katherine T Mills; Katherine M Obst; Wei Shen; Sandra Molina; Hui-Jie Zhang; Hua He; Lisa A Cooper; Jiang He Journal: Ann Intern Med Date: 2017-12-26 Impact factor: 25.391
Authors: Maxwell D Anderegg; Tyler H Gums; Liz Uribe; Christopher S Coffey; Paul A James; Barry L Carter Journal: Hypertension Date: 2016-09-06 Impact factor: 10.190
Authors: Linnea A Polgreen; Barry L Carter; Philip M Polgreen; Peter M Snyder; Daniel K Sewell; Emine O Bayman; Shelby L Francis; Jacob E Simmering; Christopher Parker; Rachel Finkelstein Journal: Contemp Clin Trials Date: 2020-10-07 Impact factor: 2.226